excluded from participation. Exposure to IPV and factors influencing decisions to offer a self-test to a sexual partner likely vary for HIV-positive women. Enrollment of participants was also limited to women attending antenatal and postpartum care. Although these services are well attended by women in Kenya, 19 our sample is not representative of all sexual partnerships. We further did not examine IPV history or distribution of self-tests to non-primary partners. Despite these limitations, our study did focus on a population that has broad reach to male partners and for whom identification of partner HIV status is of particular importance, given the elevated risk of infection during pregnancy and postpartum. [20] [21] [22] Following the World Health Organization's guidelines recommending HIVST and the launch of a national initiative to promote HIVST in Kenya, 10, 23 interventions relying on selftests are likely to become more feasible. Secondary distribution of self-tests by women to their male partners has achieved high rates of partner and couples self-testing. 12, 13 However, a high prevalence of IPV in sub-Saharan Africa will likely limit secondary distribution interventions from attaining their full potential. We encourage investigation of alternative strategies to increase HIV testing in partnerships with IPV history. Engaging men to distribute self-tests to their male peers could be an additional approach to expand testing among men.
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The authors are grateful to the study participants, the research assistants who conducted enrolment and follow-up, and the staff at the health facilities. E.M.S. and H.T. designed the study. E.M.S. analyzed the data. E. adolescents who have poorer treatment outcomes than adults with limited information on their adherence. 4, 5 With low or erratic adherence to treatment, drug levels drop, allowing a window of opportunity for virus multiplication and selection of drug-resistant viral strains. 6 Therefore, continued careful monitoring of adherence is critical to promptly identify and rectify treatment challenges.
METHODS
We conducted a trial of a lay worker-delivered treatment support intervention to improve adherence among children aged 6-15 years newly diagnosed with HIV infection, in Harare, Zimbabwe. HIV treatment was provided according to national guidelines, and treatment adherence was assessed at 48 weeks after antiretroviral therapy (ART) initiation using the AIDS Clinical Trials Group (ACTG) adherence follow-up questionnaire, adapted for this age group, and administered by research nurses. 7 Participants or participants together with their caregivers were asked whether they had missed doses over the past 3 days, over weekends in the past month (as studies have shown that some people find it difficult to take their ART medications on weekends), and over the past 3 months. Separately, for all participants, we probed about specific reasons for missing drug doses over the past month. This question was worded, "People may miss their medications for various reasons. Here is a list of possible reasons why this can happen. In the past month have you missed taking your medications because you." (Fig. 1B) . The list of reasons was derived from studies that have reported reasons for nonadherence in this age group. [8] [9] [10] In addition, participants completed a visual analog scale (VAS) to self-assess their adherence over the past month. Blood samples for HIV viral load testing were collected using routine phlebotomy and were analyzed using the dual-target COBAS AmpliPrep/ COBAS TaqMan HIV-1 Test, v2.0. 11 All statistical analyses were performed using Stata 14.0 (StataCorp, College Station, TX). Age was coded into 2 groups, 6-11 and 12-17.
RESULTS
At 48 weeks after ART initiation, of the 237 children who initiated ART, adherence data on 173 (73.0%) children [median age 11 (interquartile range 9-13) years, 55% female] were available. Of the 72 participants in the 6-11 years age group, 59 (82%) answered the adherence questions together with a relative. However, among the 12-17 years age group, 79/101 (78%) participants responded to questions alone. In 3 cases, only a relative responded, without the participant. Overall, 89 (51.4%) participants responded to the questions alone. Only 3 (1.7%) participants reported missing all their ART doses during the past 3 days, 11 (6.4%) participants reported missing doses on weekends in the past month while 14 (8.2%) reported having stopped taking their ART medicines for 2 days or longer in the past 3 months (Fig. 1A) . On the VAS, 28 (16.2%) participants reported taking less than 95% of their medication in the previous month, and 14 (8.1%) reported taking less than 90%. However, more participants (n = 47, 27.2%) reported having missed doses when asked whether they had missed doses for any of the given reasons in the past month.
The most common reasons for missing ART doses were directly linked to personal lifestyle: forgetting to take medication (n = 32, 18.7%), being away from home (n = 14, 8.1%), and falling asleep during dose times (n = 10, 5.9%). Only 1 participant reported missing doses for each of the clinical or health systemrelated reasons, such as having too many pills to take, feeling sick/ill, or clinic stock outs (Fig. 1B) . Among participants who had a viral load measurement at 48 weeks after ART initiation, 61/166 (36.7%) were not virally suppressed. Of the 28 participants who scored ,95% on the VAS and had a viral load test result 16 (59%) were unsuppressed, compared with 45/139 (32%) who scored $95%. The VAS score was strongly associated with viral suppression (odds ratio = 0.33, 95% confidence interval: 0.14 to 0.77, P = 0.01). There was no association between respondent (participant versus participant plus relative) and reported adherence, type for nonadherence or viral suppression, nor between age and the same outcomes.
CONCLUSION
In busy clinic settings, adherence is predominantly assessed by asking patients whether they have taken doses, which is subject to both desirability and recall bias. 12, 13 Our findings highlight that the greatest challenges for adherence in this group were directly linked to participants' daily routines and forgetfulness. We found that probing for possible reasons why participants may have missed doses yielded higher accuracy for identifying nonadherence than asking participants whether they were missing doses. The possible reasons for this may have been that asking specific reasons for missing doses acted as a memory trigger for participants who may have forgotten missing doses or had not considered these instances as poor adherence. We also found that although nonadherence is underreported, when participants do report nonadherence, it is a strong indicator of a high HIV viral load.
Although viral load is the gold standard to assess adherence, it is not routinely available in many resourcelimited settings. 14 Assessing short-term adherence and probing to explore the possible reasons why participants miss doses should be used by health care workers to obtain more accurate measures for ART adherence.
In our study, the responses were given by either caregivers on behalf of the child, jointly by caregivers and children, or children alone (for older children). The scales routinely used to measure reported nonadherence have been mainly designed for use among adults, and there are no corresponding scales for children. 15 
